eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
6/2011
vol. 28
 
Share:
Share:
abstract:

Original paper
Etanercept in dermatological practice – authors’ own experience in the treatment of psoriasis vulgaris and psoriatic arthritis

Zygmunt Adamski
,
Małgorzata Dudziak
,
Katarzyna Zakrzewska

Post Dermatol Alergol 2011; XXVIII, 6: 435–441
[Polish version: Post Dermatol Alergol 2011; XXVIII, 6: 442-448]
Online publish date: 2011/12/28
View full text Get citation
 
Introduction: The important role of TNF-α, a proinflammatory cytokine, in the pathogenesis of psoriasis vulgaris and psoriatic arthritis justifies the use of therapy with etanercept, which has proved to be effective in the treatment of skin lesions and joint problems.

Aim: The paper presents the authors’ own experience in evaluation of the efficacy and safety of etanercept in the treatment of psoriasis vulgaris and psoriatic arthritis in adults and in children.

Conclusions : According to the authors’ observations, etanercept administered in the dose of 50 mg once a week was characterized by patients’ high tolerance and by induction of significant skin condition improvement in patients with psoriasis vulgaris and reduction of joint complaints in patients with psoriatic arthritis, with concomitant improvement of patients’ quality of life.
keywords:

etanercept, tumour necrosis factor α, psoriatic arthritis, Psoriasis Area and Severity Index

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.